EGFR and prostate carcinoma: Pyk2 promotes distinct cancers progression by regulating different downstream signaling pathways, and EGFR signaling pathway is found to be involved in Pyk2‐regulated downstream signaling pathways in liver cancer, breast cancer, lung cancer, MM, prostate cancer, bladder cancer, SCCHN, and glioma.